Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry
Por:
Greenbaum LA, Licht C, Nikolaou V, Al-Dakkak I, Green J, Haas CS, Román-Ortiz E, Cheong HI, Sartz L, Swinford R, Tomazos I, Miller B and Cataland S
Publicada:
1 ago 2020
Ahead of Print:
19 may 2020
Categoría:
Nephrology
Resumen:
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive and potentially life-threatening disease characterized by complement-mediated thrombotic microangiopathy. Patients with aHUS may experience fatigue, which can negatively impact their lives, but there is a knowledge gap regarding disease burden in these patients.
Methods: In this longitudinal study, patients with aHUS from the Global aHUS Registry who completed patient-reported outcome assessments (Functional Assessment of Chronic Illness Therapy-Fatigue scale [FACIT-Fatigue], general health status, and work status) at >= 2 time points were assessed relative to treatment status: (i) never treated with eculizumab; (ii) on eculizumab at registry enrollment and continued therapy; and (iii) started eculizumab after registry enrollment.
Results: Patients who started eculizumab after the baseline visit (n = 23) exhibited improvements in fatigue (nearly 75% achieved clinically meaningful improvement), improved general health status (55%), and 25% to 30% rate reduction in symptoms of fatigue, weakness, irritability, nausea/vomiting, and swelling at last follow-up. Among patients already on eculizumab at registry enrollment (n = 295) and those never treated (n = 233), these parameters changed minimally relative to the baseline. Emergency room visits and hospital admissions were similar between groups. The number of health care provider visits and work days missed were higher in patients who started eculizumab after registry enrollment.
Conclusion: These real-world findings confirm the detrimental effects of aHUS on patients' daily lives, including high levels of fatigue and impairments in general health status. The results suggest clinically meaningful improvement in fatigue, other patient-reported outcomes, and symptoms with eculizumab initiation after enrollment into the aHUS registry.
Filiaciones:
Greenbaum LA:
Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA
Licht C:
The Hospital for Sick Children, Toronto, Ontario, Canada
Nikolaou V:
PAREXEL International, Uxbridge, Greater London, UK
Al-Dakkak I:
Alexion Pharmaceuticals, Inc., Boston, Massachusetts, USA
Green J:
Patient, Enrolled Columbus, Ohio, USA
Haas CS:
Department of Internal Medicine, Nephrology and Intensive Care Medicine, Philipps-University, Marburg, Germany
:
Hospital Universitario Doctor Peset, Valencia, Spain
Cheong HI:
Seoul National University Children's Hospital, Seoul, Korea
Sartz L:
Lund University, Skåne University Hospital, Lund, Sweden
Swinford R:
McGovern Medical School at UTHealth, University of Texas-Houston, Houston, Texas, USA
Tomazos I:
Alexion Pharmaceuticals, Inc., New Haven, Connecticut, USA
Miller B:
Alexion Pharmaceuticals, Inc., New Haven, Connecticut, USA
Cataland S:
The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA
Green Published, gold
|